<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340403</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0217</org_study_id>
    <secondary_id>2013-A01588-37</secondary_id>
    <nct_id>NCT02340403</nct_id>
  </id_info>
  <brief_title>Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin</brief_title>
  <acronym>INSULOX</acronym>
  <official_title>Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Neurotoxic chemotherapy, including oxaliplatin, are responsible for very disabling&#xD;
      neuropathic pain that can last for months or even years after the end of chemotherapy.&#xD;
      Currently, there is no effective neuroprotective treatment to prevent or relieve this pain.&#xD;
      The only strategy is the reduction of oxaliplatin doses or premature discontinuation of&#xD;
      therapy, with the risk of burdening the prognosis for remission. Thus, a better understanding&#xD;
      of the pathophysiology of these iatrogenic neuropathies appears necessary in order to&#xD;
      discover new potential therapeutic targets.&#xD;
&#xD;
      Preclinical works were able to demonstrate important metabolic changes in certain brain&#xD;
      structures in an animal model of oxaliplatin-induced neuropathy. A significant increase of&#xD;
      choline concentration has been found in the posterior insular cortex of neuropathic animals&#xD;
      compared with control animals. Furthermore, the concentrations of choline were positively&#xD;
      correlated to nociceptive thresholds. Thus, neuropathic pain induced by oxaliplatin would&#xD;
      involve the posterior insular cortex and would be associated with an increase in choline&#xD;
      concentration at this level. Clinical translation of these preclinical results is feasible in&#xD;
      practice since choline concentration can be determined in the brain by non-invasive magnetic&#xD;
      resonance spectroscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate a significant increase in choline concentration&#xD;
      in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives&#xD;
      will assess the correlation between metabolite concentrations in the insular cortex and&#xD;
      frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and&#xD;
      comorbidities (anxiety, pain, quality of life).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 9, 2014</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Choline concentration assessed by NMR spectroscopy in the posterior insula</measure>
    <time_frame>1 month after chemotherapy end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite concentrations assessed by NMR spectroscopy in the posterior insula</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
    <description>Metabolite (choline, myo-inositol, N-acétylaspartate, créatine, glutamate/glutamine, lactate and taurine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity (VAS and BPI questionnaire)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
    <description>(VAS and BPI questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain diagnostic 9DN4 interview questionnaire)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain intensity (NPSI questionnaire)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
    <description>NPSI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPI questionnaire</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative sensory threshold (cold, heat, vibration)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy grade</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression symptoms (HADS questionnaire)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
    <description>HADS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of chemotherapy-induced peripheral neuropathy (CIPN20 questionnaire)</measure>
    <time_frame>1 month and 6 months after chemotherapy end</time_frame>
    <description>CIPN20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (QLQ-C30 questionnaire)</measure>
    <time_frame>at 1 month and 6 months after chemotherapy end</time_frame>
    <description>(QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Neuropathy</condition>
  <condition>Painful</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin and neuropathic pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxaliplatin without neuropathic pain</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>NMR Spectroscopy</intervention_name>
    <arm_group_label>Oxaliplatin and neuropathic pain</arm_group_label>
    <arm_group_label>Oxaliplatin without neuropathic pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oxaliplatin treated patient and suffering from neuropathic pain&#xD;
&#xD;
               -  Chemotherapy (oxaliplatin based) ended&#xD;
&#xD;
               -  Pain VAS ≥ 3/10, 1 month after the chemotherapy end&#xD;
&#xD;
               -  DN4 interview score ≥ 3/7, 1 month after the chemotherapy end&#xD;
&#xD;
          -  Oxaliplatin treated patient without neuropathic pain&#xD;
&#xD;
               -  Chemotherapy (oxaliplatin based) ended&#xD;
&#xD;
               -  Pain VAS &lt; 3/10, 1 month after the chemotherapy end&#xD;
&#xD;
               -  DN4 interview score &lt; 3/7, 1 month after the chemotherapy end&#xD;
&#xD;
          -  All patients&#xD;
&#xD;
               -  right-handed&#xD;
&#xD;
               -  No contrindication to MRI&#xD;
&#xD;
               -  Free, written and informed consent&#xD;
&#xD;
               -  Affiliated to the french health system&#xD;
&#xD;
               -  Effective contraception for male or female of childbearing age&#xD;
&#xD;
               -  Performance score (WHO) ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Left-handed&#xD;
&#xD;
          -  BMI &gt; 30 kg/m²&#xD;
&#xD;
          -  Amputees of all or part of an upper limb&#xD;
&#xD;
          -  Diabetic patient&#xD;
&#xD;
          -  Painful events scheduled after enrollment (eg. surgical resection)&#xD;
&#xD;
          -  Neurological diseases (eg Parkinson's disease, stroke, migraine, fibromyalgia ...)&#xD;
&#xD;
          -  Chronic pain history before chemotherapy&#xD;
&#xD;
          -  Analgesic treatment being other than paracetamol and weak opioids&#xD;
&#xD;
          -  Alcohol consumption &gt;3 units/day (30 g/day) for men and &gt;2 units/day (20 g/day) for&#xD;
             women&#xD;
&#xD;
          -  Any unbalanced progressive disease (hepatic failure, renal impairment (creatinine&#xD;
             clearance &lt;30 mL/min), respiratory failure, congestive heart failure, myocardial&#xD;
             infarction within the past 6 months ...)&#xD;
&#xD;
          -  All active cancer&#xD;
&#xD;
          -  Patient with a pacemaker, a cochlear implant, metal implants, or any other magnetic&#xD;
             element&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnant or lactation&#xD;
&#xD;
          -  Legal incapacity (person deprived of liberty or guardianship)&#xD;
&#xD;
          -  Psychological, social, family or geographical reasons incompatible with the study&#xD;
&#xD;
          -  Already included in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Denis PEZET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathy</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Insula</keyword>
  <keyword>choline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

